Literature DB >> 33400246

Upregulation of long noncoding RNA XIST has anticancer effects on ovarian cancer through sponging miR-106a.

Ting Guo1, Donglan Yuan2, Wei Zhang3, Dandan Zhu2, Aifang Xiao4, Guangyao Mao1, Wenjuan Jiang4, Mei Lin5, Jun Wang6.   

Abstract

Ovarian cancer (OC) is a highly malignant tumor. X inactive specific transcript (XIST) was identified as a cancer-related gene, while its therapeutic effect in OC was poorly defined. The present study was designed to investigate the effectual corollary of the lncRNA XIST in OC. RT-qPCR was used to detect the XIST and miR-106a expression levels of OC tissues and cell lines. OC cell apoptosis and proliferation were detected by flow cytometry, colony formation, and CCK-8 assays. Moreover, bioinformatics analysis was used to predict the targeted miRNA of XIST. The dual-luciferase reporter and RNA pull-down assays were then used to verify the interaction between miR-106a and XIST. OC xenograft nude mice were raised to measure tumor growth. Notably, OC tissues and cells exhibited low XIST levels and high miR-106a levels. The XIST upregulation decreased the OVCAR3 and CAOV3 cell proliferation and inversely promoted cell apoptosis. miR-106a targeted the XIST. Also, the miR-106a overexpression reversed the inhibitory effects of XIST on OC cell proliferation and apoptosis. Our in vivo results suggested that XIST was involved in tumor growth deceleration, while the miR-106a reversed the effect. To conclusion, the present study demonstrated that XIST suppressed OC development via sponging miR-106a both in vitro and in vivo.

Entities:  

Keywords:  Long noncoding RNA; Ovarian cancer; XIST; miR-106a; miRNA

Mesh:

Substances:

Year:  2021        PMID: 33400246     DOI: 10.1007/s13577-020-00469-w

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  5 in total

1.  mir-106a regulates cell proliferation and apoptosis of colon cancer cells through targeting the PTEN/PI3K/AKT signaling pathway.

Authors:  Yan Qin; Zhibin Huo; Xiang Song; Xiao Chen; Xiaopeng Tian; Xinjie Wang
Journal:  Oncol Lett       Date:  2017-12-29       Impact factor: 2.967

2.  Relationship of XIST expression and responses of ovarian cancer to chemotherapy.

Authors:  Kuan-Chun Huang; Pulivarthi H Rao; Ching C Lau; Edith Heard; Shu-Kay Ng; Carolyn Brown; Samuel C Mok; Ross S Berkowitz; Shu-Wing Ng
Journal:  Mol Cancer Ther       Date:  2002-08       Impact factor: 6.261

3.  miR-183 modulated cell proliferation and apoptosis in ovarian cancer through the TGF-β/Smad4 signaling pathway.

Authors:  Junhui Zhou; Caixia Zhang; Bo Zhou; Daqiong Jiang
Journal:  Int J Mol Med       Date:  2019-01-29       Impact factor: 4.101

4.  Review article: Novel technologies in the treatment and monitoring of advanced and relapsed epithelial ovarian cancer.

Authors:  Paula Cunnea; Sally Gowers; James E Moore; Emmanuel Drakakis; Martyn Boutelle; Christina Fotopoulou
Journal:  Converg Sci Phys Oncol       Date:  2017-02-23

5.  lncRNA XIST promotes the progression of laryngeal squamous cell carcinoma by sponging miR‑144 to regulate IRS1 expression.

Authors:  Chang-Lei Cui; Yi-Ning Li; Xiang-Yan Cui; Xin Wu
Journal:  Oncol Rep       Date:  2019-12-16       Impact factor: 3.906

  5 in total
  4 in total

Review 1.  Long non-coding RNA XIST: a novel oncogene in multiple cancers.

Authors:  Jun Yang; Manlong Qi; Xiang Fei; Xia Wang; Kefeng Wang
Journal:  Mol Med       Date:  2021-12-20       Impact factor: 6.354

2.  XIST sponges miR-320d to promote chordoma progression by regulating ARF6.

Authors:  Yonggang Wang; Zhouzhou Tang; Weichun Guo
Journal:  J Bone Oncol       Date:  2022-07-16       Impact factor: 4.491

Review 3.  Long noncoding RNA XIST: Mechanisms for X chromosome inactivation, roles in sex-biased diseases, and therapeutic opportunities.

Authors:  Jianjian Li; Zhe Ming; Liuyi Yang; Tingxuan Wang; Gaowen Liu; Qing Ma
Journal:  Genes Dis       Date:  2022-04-29

Review 4.  X-Inactive-Specific Transcript: Review of Its Functions in the Carcinogenesis.

Authors:  Soudeh Ghafouri-Fard; Sepideh Dashti; Molood Farsi; Mohammad Taheri; Seyed Ali Mousavinejad
Journal:  Front Cell Dev Biol       Date:  2021-06-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.